The post Trump reaches drug pricing deal with AstraZeneca appeared on BitcoinEthereumNews.com. U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025. Nathan Howard | Reuters The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported Friday. The deal with AstraZeneca would follow a similar pact with U.S. drugmaker Pfizer, which was announced late last month. President Donald Trump and AstraZeneca CEO Pascal Soriot will announce the agreement during a White House event on Friday, MSNBC reported, citing a White House official. AstraZeneca will agree to sell drugs directly to Medicaid patients at the lowest price offered in other developed countries, or what Trump calls “most-favored nation” pricing, on a coming government website called TrumpRx.gov, according to MSNBC. Pfizer agreed to similar terms with the Trump administration and received a three-year exemption from pharmaceutical sector tariffs as part of the agreement, on the condition that it continued to invest in U.S. manufacturing. It is unclear if the deal with AstraZeneca would also include such a carveout. AstraZeneca in July said it would invest $50 billion in the U.S. by 2030. The company announced further details about those plans Friday ahead of the reported pricing deal announcement. Trump has pushed drugmakers to cut prices and build out manufacturing in the U.S., as sky-high costs for medicines relative to other developed countries irk voters across the political spectrum. As his administration threatened pharmaceutical companies with tariffs as high as 250% in recent months, many drugmakers announced significant investments in the U.S. Trump has said he aims to strike pricing deals with other major drugmakers in the weeks ahead. “If we don’t make a deal, we’re going to tariff them,” he… The post Trump reaches drug pricing deal with AstraZeneca appeared on BitcoinEthereumNews.com. U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025. Nathan Howard | Reuters The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported Friday. The deal with AstraZeneca would follow a similar pact with U.S. drugmaker Pfizer, which was announced late last month. President Donald Trump and AstraZeneca CEO Pascal Soriot will announce the agreement during a White House event on Friday, MSNBC reported, citing a White House official. AstraZeneca will agree to sell drugs directly to Medicaid patients at the lowest price offered in other developed countries, or what Trump calls “most-favored nation” pricing, on a coming government website called TrumpRx.gov, according to MSNBC. Pfizer agreed to similar terms with the Trump administration and received a three-year exemption from pharmaceutical sector tariffs as part of the agreement, on the condition that it continued to invest in U.S. manufacturing. It is unclear if the deal with AstraZeneca would also include such a carveout. AstraZeneca in July said it would invest $50 billion in the U.S. by 2030. The company announced further details about those plans Friday ahead of the reported pricing deal announcement. Trump has pushed drugmakers to cut prices and build out manufacturing in the U.S., as sky-high costs for medicines relative to other developed countries irk voters across the political spectrum. As his administration threatened pharmaceutical companies with tariffs as high as 250% in recent months, many drugmakers announced significant investments in the U.S. Trump has said he aims to strike pricing deals with other major drugmakers in the weeks ahead. “If we don’t make a deal, we’re going to tariff them,” he…

Trump reaches drug pricing deal with AstraZeneca

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025.

Nathan Howard | Reuters

The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported Friday.

The deal with AstraZeneca would follow a similar pact with U.S. drugmaker Pfizer, which was announced late last month.

President Donald Trump and AstraZeneca CEO Pascal Soriot will announce the agreement during a White House event on Friday, MSNBC reported, citing a White House official. AstraZeneca will agree to sell drugs directly to Medicaid patients at the lowest price offered in other developed countries, or what Trump calls “most-favored nation” pricing, on a coming government website called TrumpRx.gov, according to MSNBC.

Pfizer agreed to similar terms with the Trump administration and received a three-year exemption from pharmaceutical sector tariffs as part of the agreement, on the condition that it continued to invest in U.S. manufacturing.

It is unclear if the deal with AstraZeneca would also include such a carveout.

AstraZeneca in July said it would invest $50 billion in the U.S. by 2030. The company announced further details about those plans Friday ahead of the reported pricing deal announcement.

Trump has pushed drugmakers to cut prices and build out manufacturing in the U.S., as sky-high costs for medicines relative to other developed countries irk voters across the political spectrum. As his administration threatened pharmaceutical companies with tariffs as high as 250% in recent months, many drugmakers announced significant investments in the U.S.

Trump has said he aims to strike pricing deals with other major drugmakers in the weeks ahead.

“If we don’t make a deal, we’re going to tariff them,” he said late last month as he announced the Pfizer agreement.

This story is developing. Please check back for updates.

Source: https://www.cnbc.com/2025/10/10/trump-astrazeneca-drug-pricing-deal.html

Market Opportunity
OFFICIAL TRUMP Logo
OFFICIAL TRUMP Price(TRUMP)
$2.958
$2.958$2.958
-2.31%
USD
OFFICIAL TRUMP (TRUMP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Solana (SOL) Price Analysis: Can $80 Support Hold Against Mounting Pressure?

Solana (SOL) Price Analysis: Can $80 Support Hold Against Mounting Pressure?

Solana (SOL) price analysis: Testing $80 support with resistance at $85.50. ETF outflows return while RWA wallet count overtakes Ethereum for first time. The post
Share
Blockonomi2026/03/09 16:32
DOGE ETF Hype Fades as Whales Sell and Traders Await Decline

DOGE ETF Hype Fades as Whales Sell and Traders Await Decline

The post DOGE ETF Hype Fades as Whales Sell and Traders Await Decline appeared on BitcoinEthereumNews.com. Leading meme coin Dogecoin (DOGE) has struggled to gain momentum despite excitement surrounding the anticipated launch of a US-listed Dogecoin ETF this week. On-chain data reveals a decline in whale participation and a general uptick in coin selloffs across exchanges, hinting at the possibility of a deeper price pullback in the coming days. Sponsored Sponsored DOGE Faces Decline as Whales Hold Back, Traders Sell The market is anticipating the launch of Rex-Osprey’s Dogecoin ETF (DOJE) tomorrow, which is expected to give traditional investors direct exposure to Dogecoin’s price movements.  However, DOGE’s price performance has remained muted ahead of the milestone, signaling a lack of enthusiasm from traders. According to on-chain analytics platform Nansen, whale accumulation has slowed notably over the past week. Large investors, with wallets containing DOGE coins worth more than $1 million, appear unconvinced by the ETF narrative and have reduced their holdings by over 4% in the past week.  For token TA and market updates: Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here. Dogecoin Whale Activity. Source: Nansen When large holders reduce their accumulation, it signals a bearish shift in market sentiment. This reduced DOGE demand from significant players can lead to decreased buying pressure, potentially resulting in price stagnation or declines in the near term. Sponsored Sponsored Furthermore, DOGE’s exchange reserve has risen steadily in the past week, suggesting that more traders are transferring DOGE to exchanges with the intent to sell. As of this writing, the altcoin’s exchange balance sits at 28 billion DOGE, climbing by 12% in the past seven days. DOGE Balance on Exchanges. Source: Glassnode A rising exchange balance indicates that holders are moving their assets to trading platforms to sell rather than to hold. This influx of coins onto exchanges increases the available supply in…
Share
BitcoinEthereumNews2025/09/18 05:07
SOL Price Prediction: Targets $88-95 Recovery by End of March

SOL Price Prediction: Targets $88-95 Recovery by End of March

Solana trades at $83.09 with neutral RSI at 43.63. Technical analysis suggests SOL could target $88-95 by month-end if it breaks above $85 resistance, though bearish
Share
BlockChain News2026/03/09 16:03